Please sign in to follow a disease.

Extra-pulmonary neuroendocrine carcinoma

Clinical trials for Extra-pulmonary neuroendocrine carcinoma explained in plain language.

Never miss a new study

Get alerted when new Extra-pulmonary neuroendocrine carcinoma trials appear

Sign up with your email to follow new studies for Extra-pulmonary neuroendocrine carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug aims to shrink Hard-to-Treat lung cancers

Disease control Recruiting now

This phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…

Matched conditions: EXTRA-PULMONARY NEUROENDOCRINE CARCINOMA

Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Jul 25, 2026 00:00 UTC

Extra-pulmonary neuroendocrine carcinoma

Get alerted when new Extra-pulmonary neuroendocrine carcinoma trials appear

New drug aims to shrink Hard-to-Treat lung cancers